Literature DB >> 11021986

Effect of corticotropin releasing factor receptor 1 antagonist on extracellular norepinephrine, dopamine and serotonin in hippocampus and prefrontal cortex of rats in vivo.

K Isogawa1, J Akiyoshi, T Hikichi, Y Yamamoto, T Tsutsumi, H Nagayama.   

Abstract

Corticotropin releasing factor (CRF) is a major mediator of adaptive responsiveness to stress. We measured changes in extracellular concentrations of catecholamine and indoleamines in freely moving rats in response to administration of CRF1 antagonist CP-154,526 by using in vivo microdialysis. Dialysis probes were placed stereotaxically in either the hippocampus or the prefrontal cortex. We examined the response in the hippocampus or the prefrontal cortex to 32.0 mg/kg i.p. administration of CP-154,526. CP-154,526 reduced the extracellular concentration of norepinephrine (NE) from 30 min to 180 min and 5-hydroxytryptamine (5-HT) from 30 min to 60 min after injection in the hippocampus. CP-154,526 did not remarkably change dopamine (DA). There were no significant differences between CP-154,526 and vehicle in NE, 5-HT and DA in the prefrontal cortex. The present results indicate that CRF1 receptor antagonist produced a decrease in dialysate concentration of NE and 5-HT, but not DA, in the hippocampus. These results suggest that the CRH-1 receptor antagonist suppresses the release of NE and 5-HT in the hippocampus. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11021986     DOI: 10.1054/npep.2000.0806

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  9 in total

Review 1.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

2.  Corticotropin-releasing factor and noradrenergic signalling exert reciprocal control over startle reactivity.

Authors:  Jodi E Gresack; Victoria B Risbrough
Journal:  Int J Neuropsychopharmacol       Date:  2010-12-21       Impact factor: 5.176

3.  Contrasting effects of pretraining, posttraining, and pretesting infusions of corticotropin-releasing factor into the lateral amygdala: attenuation of fear memory formation but facilitation of its expression.

Authors:  Koichi Isogawa; David E A Bush; Joseph E LeDoux
Journal:  Biol Psychiatry       Date:  2012-10-01       Impact factor: 13.382

Review 4.  Stress, alcohol and drug interaction: an update of human research.

Authors:  Magdalena Uhart; Gary S Wand
Journal:  Addict Biol       Date:  2008-10-09       Impact factor: 4.280

5.  Corticotropin-releasing factor in the basolateral amygdala enhances memory consolidation via an interaction with the beta-adrenoceptor-cAMP pathway: dependence on glucocorticoid receptor activation.

Authors:  Benno Roozendaal; Gustav Schelling; James L McGaugh
Journal:  J Neurosci       Date:  2008-06-25       Impact factor: 6.167

6.  Moderate perinatal arsenic exposure alters neuroendocrine markers associated with depression and increases depressive-like behaviors in adult mouse offspring.

Authors:  Ebany J Martinez; Bethany L Kolb; Angela Bell; Daniel D Savage; Andrea M Allan
Journal:  Neurotoxicology       Date:  2008-05-21       Impact factor: 4.294

7.  Differential blockade of CRF-evoked behaviors by depletion of norepinephrine and serotonin in rats.

Authors:  Owen Howard; Gregory V Carr; Tiffany E Hill; Rita J Valentino; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2008-05-31       Impact factor: 4.530

8.  CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents.

Authors:  T N Douma; M J Millan; D Boulay; G Griebel; P M Verdouw; K G Westphal; B Olivier; L Groenink
Journal:  Psychopharmacology (Berl)       Date:  2013-11-02       Impact factor: 4.530

9.  Functional Interplay of Type-2 Corticotrophin Releasing Factor and Dopamine Receptors in the Basolateral Amygdala-Medial Prefrontal Cortex Circuitry.

Authors:  H E Yarur; J Zegers; I Vega-Quiroga; J Novoa; F Ciruela; M E Andres; K Gysling
Journal:  Int J Neuropsychopharmacol       Date:  2021-03-17       Impact factor: 5.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.